Cagrilintide: What 7 Users Report
Also known as:
often mentioned with:
community guides:
Related GLP-1 pages:
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
What is cagrilintide?
Cagrilintide is a long-acting analogue of amylin, a hormone released with insulin that slows stomach emptying and signals fullness. Novo Nordisk developed it mainly as half of CagriSema (cagrilintide plus semaglutide). In trials, cagrilintide alone produced modest weight loss and the combination produced more than semaglutide alone. Reported side effects are mostly gastrointestinal: nausea, constipation, vomiting and reduced appetite. Cagrilintide on its own is not an approved medicine. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report
Tagged confessions include #162, #509, #587, #618, #668 and #734. Most describe cagrilintide alongside a GLP-1 such as retatrutide or semaglutide, so effects cannot be attributed to cagrilintide alone. Appetite suppression and GI symptoms are the recurring themes.
Anonymous cagrilintide reports
If you have used cagrilintide, alone or with a GLP-1, submit what happened.
Submit yoursCommunity Q&A
- What does cagrilintide do?
- It mimics amylin: slower gastric emptying and stronger fullness signals. Trials studied it for weight management, mostly combined with semaglutide.
- Is cagrilintide approved?
- Not as a standalone drug. It is developed as part of CagriSema.
- What are cagrilintide side effects?
- Trial and user reports centre on nausea, constipation, vomiting and reduced appetite.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.